Vir Biotechnology, Inc., a clinical-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops VIR-2218 and VIR-3434 for the treatment of hepatitis B virus VIR-2482 for the prevention of influenza A virus VIR-1111 for the prevention of human immunodeficiency virus and VIR-2020 for the prevention of tuberculosis. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited a collaboration and license agreement with Alnylam Pharmaceuticals, Inc. a collaboration, license, and option agreement with Visterra, Inc. license agreements with The Rockefeller University and MedImmune, Inc. a collaboration with WuXi Biologics and a collaborative research agreement with Generation Bio., as well as GlaxoSmithKline Intellectual Property Development Limited, GlaxoSmithKline Biologicals SA., and Alnylam Pharmaceuticals, Inc. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies for potential COVID-19 treatment and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. Vir Biotechnology, Inc. was founded in 2016 and is headquartered in San Francisco, California.